{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:11Z","timestamp":1793896091485,"version":"4.8.0"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,3,30]]},"abstract":"<jats:p>We report a rare case of drug-induced intestinal lung disease (ILD) secondary to adalimumab, a tumour necrosis factor alpha-receptor blocker. A 52-year-old smoker with ankylosing spondylitis, treated with adalimumab, presented with progressive breathlessness. A high resolution CT chest demonstrated predominantly upper-zone patchy ground glass changes and small bilateral pleural effusions. Bronchoscopy and bronchoalveolar lavage showed no evidence of infection or malignant cells and an echocardiogram was normal. The working diagnosis was that of possible adalimumab-induced ILD. Adalimumab was subsequently stopped. The patient\u2019s breathlessness and cough improved on cessation of the drug. A further CT chest several months later showed resolution of the ground glass changes. Adalimumab-induced ILD is rare. We review the literature surrounding this and discuss the diagnostic challenges. This case highlights the importance of considering the possibility of drug-induced lung disease in patients taking adalimumab.<\/jats:p>","DOI":"10.1136\/bcr-2018-224375","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T05:25:24Z","timestamp":1526361924000},"page":"bcr-2018-224375","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Case of drug-induced interstitial lung disease secondary to adalimumab"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6217-2607","authenticated-orcid":false,"given":"Seema","family":"Alaee","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Great Western Hospital, Swindon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Great Western Hospital, Swindon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.1","first-page":"77","article-title":"Adalimumab (Humira) induced acute lung injury","volume":"14","author":"Kohli","year":"2013","journal-title":"Am J Case Rep"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.11.002"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.3","first-page":"53","article-title":"Adalimumab induced pulmonary sarcoid reaction","volume":"10","author":"Bhargava","year":"2013","journal-title":"Respir Med Case Rep"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.4","doi-asserted-by":"publisher","DOI":"10.1148\/radiographics.20.5.g00se081245"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.09.005"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/1744666X.2013.811173","article-title":"Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis","volume":"9","author":"Atzeni","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.8","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.7.2010120"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/728471","article-title":"Cardiopulmonary manifestations of ankylosing spondylitis","volume":"2011","author":"Momeni","year":"2011","journal-title":"Int J Rheumatol"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3748\/wjg.v21.i7.2260","article-title":"Adalimumab-induced interstitial pneumonia in a patient with Crohn\u2019s disease","volume":"21","author":"Casanova","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"2025082703190612000_2018.may14_2.bcr-2018-224375.12","doi-asserted-by":"crossref","unstructured":"Zhang Z , Fan W , Yang G , et al . Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2018.","DOI":"10.1136\/bmjopen-2016-012567"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-224375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:19:15Z","timestamp":1756289955000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-224375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":12,"alternative-id":["10.1136\/bcr-2018-224375"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-224375","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}